Inhalte werden geladen...
Mika automates your financial processes using secure generative AI.
Get Mika GmbH (mika) is a GenAI startup founded in 2023 and based in Berlin.
Independent B2B performance index (0–100 points). It is calculated mathematically and without subjective influence from four verified pillars: company stability, aggregated feedback from publicly available online sources, documented compliance certifications, and operational transparency.
Headquarters
Berlin, Germany
Employees
1
Founded
2023
Get Mika GmbH (mika) is a GenAI startup founded in 2023 and based in Berlin. The company develops an innovative, AI-based cloud solution specifically designed to automate accounting and tax processes for small businesses, startups, as well as GmbHs and UGs. The platform combines generative artificial intelligence with a final review by human experts. This ensures high accuracy and compliance while minimizing manual effort for founders. Core features include the 'Upload & Relax' principle, where receipts are simply uploaded via photo, email forwarding, or a direct Google Drive connection and automatically booked. In addition, mika offers automatic preparation of advance VAT returns and seamless DATEV export for existing accounting systems. With this hybrid approach of AI efficiency and expert validation, mika enables simple, time-saving, and cost-effective financial management that adapts flexibly to the needs of modern digital businesses.
No verified certifications (such as ISO 27001 or SOC 2) are currently listed for this provider. Information about compliance with standards such as GoBD or GDPR may still be available.
Ask the AI assistant on this page for current compliance and security details. It researches live information from publicly available sources.
Ask about pricing, features, integrations, or comparisons. Our AI assistant can help with up-to-date information.
Get Mika GmbH, developer of the oncological platform 'Mika', is recording significant progress in establishing its digital health application (DiGA) to support cancer patients. Through strategic partnerships with statutory health insurance funds and leading pharmaceutical companies, its reach is continuously being expanded in the DACH region and internationally, particularly in the UK. The product focuses on personalized symptom tracking and psycho-oncological support to improve patients' quality of life during cancer therapy.
Latest updates
This section will soon show highlights from social networks, including community perspectives, trends, and recurring topics.